Browsing by Author "Ozerdem, A"

Now showing 1 - 9 of 9
  • No Thumbnail Available
    Item
    Alterations in BDNF (brain derived neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor) serum levels in bipolar disorder: The role of lithium
    Tunca, Z; Ozerdem, A; Ceylan, D; Yalçin, Y; Can, G; Resmi, H; Akan, P; Ergor, G; Aydemir, Ö; Cengisiz, C; Doyurana, K
    Objective: Brain-derived neurotrophic factor (BDNF) has been consistently reported to be decreased in mania or depression in bipolar disorders. Evidence suggests that Glial cell line-derived neurotrophic factor (GDNF) has a role in the pathogenesis of mood disorders. Whether GDNF and BDNF act in the same way across different episodes in bipolar disorders is unclear. Method: BDNF and GDNF serum levels were measured simultaneously by enzyme-linked immunosorbent assay (ELISA) method in 96 patients diagnosed with bipolar disorder according to DSM-IV (37 euthymic, 33 manic, 26 depressed) in comparison to 61 healthy volunteers. SCID-I and SCID-non patient version were used for clinical evaluation of the patients and healthy volunteers respectively. Correlations between the two trophic factor levels, and medication dose, duration and scrum levels of lithium or valproate were studied across different episodes of illness. Results: Patients had significantly lower BDNF levels during mania and depression compared to euthymic patients and healthy controls. GDNF levels were not distinctive. However GDNF/BDNF ratio was higher in manic state compared to euthymia and healthy controls. Significant negative correlation was observed between BDNF and GDNF levels in euthymic patients. While BDNF levels correlated positively, GDNF levels correlated negatively with lithium levels. Regression analysis confirmed that lithium levels predicted only GDNF levels positively in mania, and negatively in euthymia. Limitations: Small sample size in different episodes and drug-free patients was the limitation of thestudy. Conclusion: Current data suggests that lithium exerts its therapeutic action by an inverse effect on BDNF and GDNF levels, possibly by up regulating BDNF and down regulating GDNF to achieve euthymia. (C) 2014 Elsevier B.V. All rights reserved.
  • No Thumbnail Available
    Item
  • No Thumbnail Available
    Item
    Towards an assessment tool for mixed depression: a multinational study using modified Hypomania Checklist (mHCL) in bipolar and unipolar depression
    Altinbas, K; Ozerdem, A; Yalin, N; Ersoy, Z; Aydemir, O; Prieto, M; Oztekin, S; Aydin, E; Fuentes, M; Feeder, S; Frye, MA
  • No Thumbnail Available
    Item
    Development, reliability and validity of bipolar disorder functioning questionnaire
    Aydemir, O; Eren, I; Savas, H; Kalkan-Oguzhanoglu, N; Kocal, N; Devrimci-Ozguven, H; Akkaya, C; Devrim-Basterzi, A; Karlidag, R; Yenilmez, C; Ozerdem, A; Kora, K; Tamam, L; Gulseren, S; Oral, T; Vahip, S
  • No Thumbnail Available
    Item
    A multinational study to pilot the modified Hypomania Checklist (mHCL) in the assessment of mixed depression
    Altinbas, K; Ozerdem, A; Prieto, ML; Fuentes, ME; Yalin, N; Ersoy, Z; Aydemir, O; Quiroz, D; Oztekin, S; Geske, JR; Feeder, SE; Angst, J; Frye, MA
    Background: Mixed depression is a common, dimensional phenomenon that is increasingly recognized in unipolar and bipolar disorders. We piloted a modified version of the Hypomania Checklist (mHCL-32) to assess the prevalence and clinical correlates of concurrent manic (hypo) symptoms in depressed patients. Methods: The mHCL-32, Young Mania Rating Scale (YMRS) and Hamilton Rating Scale for Depression (IAMD-24) were utilized in the assessment of unipolar (UP=61) and bipolar (BP=44) patients with an index major depressive episode confirmed by the Structured Clinical Interview for DSM-IV (SCID). Differential mHLC-32 item endorsement was compared between UP and BR Correlation analyses assessed the association of symptom dimensions measured by mHCL-32, YMRS and HAMD-24. Results: There was no significant difference between mood groups in the mean rnHCL-32 and YMRS scores. Individual mHLC-32 items of increased libido, quarrels, and caffeine intake were endorsed more in BP vs. UP patients. The mHCL-32 active elevated subscale score was positively correlated with the YMRS in BP patients and negatively correlated with HAMD-24 in UP patients. Conversely, the mHCL-32 irritable risk taking subscale score was positively correlated with HAMD-24 in BP and with YMRS in UP patients. Limitations: Small sample size and cross-sectional design. Conclusion: Modifying the HCL to screen for (hypo) manic symptoms in major depression may have utility in identifying mixed symptoms in both bipolar vs. unipolar depression. Further research is encouraged to quantify mixed symptoms with standardized assessments. (C) 2013 Published by Elsevier B.V.
  • No Thumbnail Available
    Item
    Different patterns of manic/hypomanic symptoms in depression: A pilot modification of the hypomania checklist-32 to assess mixed depression
    Prieto, ML; Youngstrom, EA; Ozerdem, A; Altinbas, K; Quiroz, D; Aydemir, O; Yalin, N; Geske, JR; Feeder, SE; Angst, J; Frye, MA
    Background: There are no self-report scales that assess manic/hypomanic symptoms in patients with depression. The aim of this study was to explore the use of a modified screening instrument for bipolar disorder to assess current manic/hypomanic symptoms in patients with a depressive episode. Methods: The study sample consisted of 188 patients with Structured Clinical Interview for DSM-IV-TR disorders (SCID) confirmed bipolar or major depressive disorder. We modified the Hypomania Checklist-32 (mHCL-32) to assess current instead of lifetime symptoms. An Exploratory Factor Analysis (EFA) was conducted to identify clusters of mHCL-32 items that were endorsed concurrently. A Latent Class Analysis (LCA) was carried out to identify groups of patients with similar mHCL-32 item endorsement patterns. Results: The EPA identified 3 factors: factor #1 (elation-disinhibition-increased goal directed activity), factor #2 (risk-taking-impulsivity-substance use) and factor #3 (distractibility-irritability). The LCA yielded 3 classes (2 showing manic/hypomanic features). While class #1 patients endorsed more items related to disinhibition and racing thoughts, class #2 patients recognized more items associated with irritability and substance use Limitations: Lack of an adequate gold standard measure of mixed depression to compare to, the cross-sectional design and the lack of a validation sample. Conclusions: The mHCL-32 scale allowed a comprehensive and convergent delineation of hypomanic/manic symptoms in depression. Further validation of these findings is needed. (C) 2014 Elsevier B.V. All rights reserved,
  • No Thumbnail Available
    Item
    Effect of gender on the co-occuring manic symptoms in depression
    Ozerdem, A; Prieto, ML; Yalin, N; Quiroz, D; Altinbas, K; Aydemir, O; Ersoy, Z; Feeder, SE; Geske, JR; Fuentes, M; Frye, MA
  • No Thumbnail Available
    Item
    Exploratory factor analysis of mixed depression utilizing a modified version of Hypomania Checklist 32 (mHCL-32)
    Prieto, ML; Ozerdem, A; Quiroz, D; Altinbas, K; Aydemir, O; Yalin, N; Feeder, SE; Geske, JR; Frye, MA
  • No Thumbnail Available
    Item
    The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC)
    Yatham, LN; Torres, IJ; Malhi, GS; Frangou, S; Glahn, DC; Bearden, CE; Burdick, KE; Martínez-Arán, A; Dittmann, S; Goldberg, JF; Ozerdem, A; Aydemir, O; Chengappa, KNR
    Objectives: Although cognitive impairment is recognized as an important clinical feature of bipolar disorder, there is no standard cognitive battery that has been developed for use in bipolar disorder research. The aims of this paper were to identify the cognitive measures from the literature that show the greatest magnitude of impairment in bipolar disorder, to use this information to determine whether the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB), developed for use in schizophrenia, might be suitable for bipolar disorder research, and to propose a preliminary battery of cognitive tests for use in bipolar disorder research. Methods: The project was conducted under the auspices of the International Society for Bipolar Disorders and involved a committee that comprised researchers with international expertise in the cognitive aspects of bipolar disorder. In order to identify cognitive tasks that show the largest magnitude of impairment in bipolar disorder, we reviewed the literature on studies assessing cognitive functioning (including social cognition) in bipolar disorder. We further provided a brief review of the cognitive overlap between schizophrenia and bipolar disorder and evaluated the degree to which tasks included in the MCCB (or other identified tasks) might be suitable for use in bipolar disorder. Results: Based on evidence that cognitive deficits in bipolar disorder are similar in pattern but less severe than in schizophrenia, it was judged that most subtests comprising the MCCB appear appropriate for use in bipolar disorder. In addition to MCCB tests, other specific measures of more complex verbal learning (e.g., the California Verbal Learning Test) or executive function (Stroop Test, Trail Making Test-part B, Wisconsin Card Sorting Test) also show substantial impairment in bipolar disorder. Conclusions: Our analysis reveals that the MCCB represents a good starting point for assessing cognitive deficits in research studies of bipolar disorder, but that other tasks including more complex verbal learning measures and tests of executive function should also be considered in assessing cognitive compromise in bipolar disorder. Several promising cognitive tasks that require further study in bipolar disorder are also presented.